The Effect of Eszopiclone 3 Mg Compared to Placebo on Daytime Function in Subjects With Insomnia Related to Rheumatoid Arthritis
Information source: Sepracor, Inc.
Information obtained from ClinicalTrials.gov on October 19, 2007
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Insomnia; Arthritis, Rheumatoid
Intervention: Eszopiclone (Drug)
Phase: Phase 3
Status: Completed
Sponsored by: Sepracor, Inc.
Summary
To demonstrate subjective sleep efficacy of eszopiclone 3 mg in subjects with insomnia related to rheumatoid arthritis (RA).
Clinical Details
Official title:
The Effect of Eszopiclone 3 Mg Compared to Placebo on Daytime Function in Subjects With Insomnia Related to Rheumatoid Arthritis
Study design: Interventional, Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study
Eligibility
Minimum age: 25 Years.
Maximum age: 64 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Patients with insomnia assoiated with Rheumatoid arthritis (RA).
Exclusion Criteria:
-
Locations and Contacts
Additional Information
Last updated: August 23, 2006
|
